Skip to main content

Table 1 Summary of clinical trials utilizing IL-2 in anti-cancer immunotherapy

From: Tumor-related interleukins: old validated targets for new anti-cancer drug development

Treatment Cancer type Overall response rate Side effects Ref.
IL-2 monotherapy Metastatic Melanoma,
Renal cell carcinoma
6.6% complete response
19%
Expected IL-2 related side effects [46]
IL-2 plus IFN-α2b Metastatic Renal Cancer 9.9% Expected IL-2 related side effects [187]
IL-2 plus IFN-α2b plus chemotherapy Metastatic Melanoma 19.5% Chemotherapy related toxicity, some of IL-2 related side effects [188]
IL-2 plus
Ipilimumab (anti-CTLA-4 antibody)
Stage IV Melanoma 22% Expected IL-2 related side effects, Ipilimumab related autoimmune toxicities [47]
IL-2 plus gp100 vaccine Stage III Melanoma 16% Some IL-2 related toxicity [189]
IL-2 plus IL-2 expanded TILs Melanoma 48.4% Expected IL-2 related side effects [190]
IL-2 plus LAK cells
Darleukin (L19IL2)
Daromun (L19IL2 + L19TNF)
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal cancer,
non-Hodgkin’s Lymphoma,
Stage IIIB/C melanoma
Stage IIIB/C and IVM1a melanoma
21% 35%
No observed response
No observed response
53.9%, 25% complete remission
55%, 5% complete remission
Expected IL-2 related side effects
Limited IL-2 related side effects
Limited IL-2 related side effects
[45, 191]
[192]
[193]